dezocine and Carcinoma--Hepatocellular

To analyse the impact of dezocine-remifentanil intravenous anaesthesia on perioperative signs, serum tumour necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in liver cancer patients undergoing radiofrequency ablation (RFA).. An experimental study.. Renmin Hospital of Wuhan University, Wuhan, China, from January 2017 to February 2018.. Eighty patients with small hepatocellular carcinoma (SHCC) were selected as the research object. They were divided into Group A and Group B with the random number table method, with 40 cases in each group. Group A were given dezocine-remifentanil intravenous anaesthesia and Group B were given midazolam-remifentanil intravenous anaesthesia. Patients' situations in the surgery were compared between the two groups. Changes in heart rate (HR), mean arterial pressure (MAP) and blood oxygen saturation (SpO. Compared with midazolam-remifentanil intravenous anaesthesia, the dezocine-remifentanil method has a better analgesic effect, shorter wake-up time, and can effectively regulate the expression of inflammatory cytokines TNF-α and IL-6. However, the effect of remifentanil on the respiratory function is dose-dependent. Therefore, respiratory cycle monitoring and management should be strengthened during the surgery.

Topics: Adult; Aged; Analgesics, Opioid; Anesthesia, Intravenous; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Interleukin-6; Liver Neoplasms; Male; Middle Aged; Radiofrequency Ablation; Remifentanil; Tetrahydronaphthalenes; Treatment Outcome; Tumor Necrosis Factor-alpha